YOLFTbeta
XSpray Pharma AB

XSpray Pharma AB

XSPRAY · ST · Healthcare / Biotechnology

11.02SEK-0.26 (-2.30%)

Price History

Full chart

Market Stats

Previous Close11.28
Open10.60
Day Range10.60 – 12.00
52-Week Range9.06 – 36.15
Volume65.23K
Market Cap523.48M
P/E (TTM)0.00
Forward P/E0.00
EPS-3.69
Dividend Yield0.00%
Beta-0.13
50-Day Avg11.63
200-Day Avg20.66

About

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Blake Leitch
  • Employees24
  • HeadquartersScheeles väg 2, Solna, Sweden, 171 65, Sweden
  • Websitehttps://www.xspraypharma.com

Leadership

  • Dr. Per Andersson Ph.D.Chief Scientific Officer · b. 1967
  • Mr. Blake LeitchChief Executive Officer · b. 1975
  • Dr. Mustafa Demirbüker Ph.D.Co-Founder and Science Director
  • Mr. Niklas AdenborgChief Financial Officer · b. 1992
  • Ms. Linda GlimbergChief Operating Officer · b. 1974
  • Dr. Mikael Von Euler-ChelpinChief Medical Officer · b. 1953

Financials

Income Statement

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.64M792.00K331.55K277.00K0000000
Growth (%)--78.24%-58.14%-16.45%-100.00%------
Cost of Revenue5.29M-6.19M-4.13M-4.80M1.41M8.87M9.53M9.19M8.55M5.58M
Gross Profit-1.65M6.99M4.47M277.00K-4.80M-1.41M-8.87M-9.53M-9.19M-8.55M-5.58M
Gross Margin-45.44%881.94%1347.10%100.00%-------
Operating Expense10.43M11.04M17.74M23.49M40.90M52.05M89.08M123.54M172.54M274.69M156.27M
Operating Income-12.09M-4.06M-13.28M-23.22M-45.70M-53.46M-97.95M-133.07M-181.73M-283.24M-161.85M
Operating Margin-332.09%-512.50%-4004.80%-8381.59%-------
EBITDA-11.48M-3.40M-12.65M-19.07M-40.90M-50.99M-87.82M-122.13M-169.81M-277.76M-156.27M
EBITDA Margin-315.38%-428.71%-3815.76%-6884.84%-------
Net Income-12.09M-4.10M-13.20M-23.10M-45.84M-52.30M-96.70M-130.27M-179.67M-285.52M-171.44M
Net Income Margin-332.17%-517.30%-3980.86%-8338.63%-------
R&D--3.35M5.54M3.43M6.55M38.57M22.22M33.59M81.98M8.61M
R&D as % of Total Revenue--1011.62%1998.56%-------
Interest Expense3.00K59.00K88131.00K69.00K6.00K4.00K12.00K675.00K1.93M16.85M
Interest Expense % of Total Revenue0.08%7.45%0.27%11.19%-------

Balance Sheet

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets14.95M51.86M161.41M312.49M400.67M605.30M622.90M585.43M765.26M796.34M769.35M
Total Liabilities2.69M5.39M5.75M10.77M26.96M22.72M31.15M29.41M71.85M173.25M164.70M
Total Equity12.26M46.47M155.66M301.72M373.71M582.59M591.75M556.02M693.41M623.10M604.65M
Cash11.85M28.80M115.51M221.27M209.87M325.60M271.88M120.17M166.30M208.24M153.75M
Total Debt----5.33M4.86M3.23M2.13M36.81M128.22M170.11M
Net Debt-11.85M-28.80M-115.51M-221.27M-204.54M-320.74M-268.65M-118.04M-129.50M-80.02M16.36M

Cash Flow

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.96M-1.74M-11.04M-17.75M-34.24M-47.79M-51.61M-110.18M-203.28M-222.37M-193.16M
Investing Cash Flow-215.00K-19.61M-24.63M-47.01M-91.99M-96.83M-105.82M-135.34M-65.88M-42.14M-29.19M
Financing Cash Flow22.55M38.31M122.38M170.46M114.84M260.35M103.71M93.81M315.59M306.11M168.29M
Capital Expenditure214.00K19.61M24.63M46.96M91.99M97.21M95.96M128.29M54.10M42.14M29.19M
Free Cash Flow-13.18M-21.35M-35.67M-64.70M-126.23M-145.00M-147.57M-238.47M-257.38M-264.51M-222.35M
Dividends Paid-----1.01M2.21M2.18M---
FCF to OCF101.65%1224.43%323.14%364.61%368.70%303.40%285.95%216.43%126.62%118.95%115.11%
Dividend Paid to FCF------0.70%-1.50%-0.91%---

Earnings

Report DateSep 30, 2017Feb 19, 2018May 14, 2018Aug 24, 2018Nov 28, 2018Feb 14, 2019May 16, 2019Aug 29, 2019Nov 14, 2019Feb 28, 2020May 14, 2020Jul 31, 2020Nov 20, 2020Feb 25, 2021May 6, 2021Aug 6, 2021Oct 26, 2021Feb 18, 2022May 6, 2022Aug 5, 2022Nov 9, 2022Feb 15, 2023May 4, 2023Aug 2, 2023Nov 8, 2023Feb 14, 2024May 8, 2024Aug 7, 2024Nov 6, 2024Feb 12, 2025May 7, 2025Aug 15, 2025Nov 5, 2025Feb 12, 2026May 7, 2026Aug 6, 2026
EPS Estimate------------------1.48-2.53-0.93-2.53-2.14------1.55-1.39-1.82-1.81-1.71-1.651.75--
EPS Actual-0.21-0.38-0.12-0.50-0.30-0.75-0.56-0.73-0.70-1.00-0.63-0.92-0.69-0.81-0.73-0.89-0.73-2.62-0.92-1.40-1.39-2.48-1.54-2.27-1.59-1.85-2.17-1.64-2.44-2.36-1.14-2.35-1.25-0.89-0.82-0.87
Surprise------------------77.03%63.64%-50.54%45.06%-15.89%------5.81%-75.54%-29.67%37.02%-37.43%24.24%-150.86%--
Timing-After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market--

Key Statistics & Ratios

Market Cap523.48M
Enterprise Value430.18M
Trailing P/E0.00
Forward P/E0.00
Price / Sales212.28
Price / Book0.73
EPS-3.69
Book Value13.45
Revenue (TTM)2.47M
Gross Profit (TTM)2.47M
EBITDA-144.96M
Profit Margin0.00%
Operating Margin-464.62%
Return on Equity-27.19%
Return on Assets-12.20%
Shares Outstanding47.42M
Shares Float33.91M
Beta-0.13
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%